Skip to content
ClinCalc Pro
Menu
Haematology Oncology Strong — NICE NG143 / Carmona-Bayonas 2015

CISNE Score for Febrile Neutropenia

Clinical Index of Stable Febrile Neutropenia (CISNE) — identifies low-risk solid tumour patients with febrile neutropenia suitable for oral antibiotics and early discharge.

Chronic heart failure, coronary artery disease, arrhythmia, hypertension requiring treatment

Score interpretation

Low Risk — Oral / Outpatient 0

CISNE 0: Very low risk of serious complications (< 2%). Eligible for oral antibiotics and early discharge.

→ Oral ciprofloxacin 500–750 mg BD + amoxicillin-clavulanate 625 mg TDS (or oral co-amoxiclav 625 mg TDS alone if fluoroquinolone-resistant risk). Discharge with clear safety-net instructions. Return if: fever persists > 48h, new symptoms, or clinical deterioration. Follow-up in 24–48 hours.

Intermediate Risk 1–2

CISNE 1–2: Intermediate risk (~6% serious complications). Consider inpatient IV antibiotics.

→ IV piperacillin/tazobactam 4.5g TDS or ceftazidime 2g TDS (NICE NG143). Monitor 24–48h. Reassess for de-escalation to oral if clinically stable after 24h. Blood cultures × 2 before antibiotics. MASCC score as complementary tool.

High Risk — IV Antibiotics Required 3–99

CISNE ≥ 3: High risk (> 15% serious complications). Inpatient IV antibiotics mandatory.

→ IV piperacillin/tazobactam 4.5g TDS. Add IV gentamicin if septic shock or Gram-negative suspicion. Vancomycin if line-related infection or MRSA risk. Blood cultures × 2, urine, CXR. Daily review. Consider antifungal after 4–7 days of persistent fever (caspofungin or fluconazole). G-CSF if delayed recovery.

Interpretation bands for the CISNE. Apply clinical judgement and local guidance.

References

Related

Curated clinical cross-links plus same-class fallbacks.

Decision support only — verify against a current formulary, NICE, or your local guideline before clinical use.